Positive results for GSK’s anaemia drug daprodustat
Daprodustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor in development for anaemia due to chronic kidney disease
Read More
Tag: GlaxoSmithKline
CHMP recommends Nucala for three new indications
Positive opinions recommend approval for mAb in three additional eosinophil-driven diseases
Read More
GSK’s shingles vaccine Shingrix gains UK license
Jab aimed at adults aged 50 years and older and those at increased risk
Read More
GSK, SK to compare COVID-19 vaccine candidate to AZ’s jab
Phase III trial will use AZ’s COVID-19 vaccine as an active comparator
Read More
Accelerated FDA approval for GSK’s Jemperli
Indicated for the treatment of of dMMR recurrent or advanced solid tumours
Read More
GSK, CureVac’s COVID-19 vaccine candidate shows promise in preclinical study
Preclinical study shows high protective efficacy in primates for Beta, Delta and Lambda variants
Read More
GSK and Alector ink neurodegenerative diseases partnership
Under the terms of the collaboration, Alector could receive up to $1.5bn in milestone payments
Read More
GSK’s PD-1 inhibitor Jemperli approved in the UK
Conditional marketing authorisation granted for the treatment of recurrent or advanced endometrial cancer
Read More
GSK, Sanofi launch late-stage COVID-19 vaccine study
The study will include more than 35,000 volunteers aged 18 years and older
Read More
Sanofi, GSK’s COVID-19 vaccine achieves positive Phase II results
Companies previously delayed vaccine programme after Phase I/II study results found a low immune response in older adults
Read More
GSK, CureVac’s next-gen COVID-19 jab generates positive preclinical data
Vaccine induced strong immune responses in a rat model during preclinical testing
Read More
FDA approves GSK’s Jemperli for dMMR endometrial cancer
PD-1 inhibitor approved to treat patients with specific biomarker
Read More
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
- Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination
- HUTCHMED begins phase 3 stage of pancreatic cancer trial
- Zenas reports strong phase 3 results for obexelimab in IgG4-related disease
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
